Publications:
Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24.
Alaoui-Jamali MA and Lougheed NC. Herbal products-chemotherapy drug interactions from a pharmacological perspective. In “Alternative and Complementary Therapies for Cancer: A Comprehensive Guide on Current Practice and Issues with Conventional Practice; Editors: M Alaoui-Jamali and Ling Peng. In press
Alaoui-Jamali M, Toliopoulos P, and Krikor B. Protein trafficking signalling in invasive cancers and therapeutic implications. "Signal Transduction in Cancer Metastasis". Cancer Metastasis Biology & Treatment Series by Springer Life Sciences–Biomedical Unit, 2009
Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, Laboissiere S, Alaoui-Jamali MA. Serum Proteomic Approach for the Identification of Serum Biomarkers Contributed by Oral Squamous Cell Carcinoma and Host Tissue Microenvironment (dagger).
J Proteome Res. 2009 May 1;8(5):2173-2185.
Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA. Fascin regulates prostate cancer cell invasion and is
associated with metastasis and biochemical failure in prostate cancer.
Clin Cancer Res. 2009 Feb 15;15(4):1376-83
Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.
Br J Cancer. 2009 Feb 24;100(4):633-43.
Poondra RR, Kumar NN, Bijian K, Prakesch M, Campagna-Slater V, Reayi A, Reddy PT, Choudhry A, Barnes ML, Leek DM, Daroszewska M, Lougheed C, Xu B, Schapira M, Alaoui-Jamali MA, Arya P. Discovery of Indoline-Based, Natural-Product-like Compounds as Probes of Focal Adhesion Kinase Signaling Pathways. J Comb Chem. 2009 Jan 15.
Prakesch M, Bijian K, Campagna-Slater V, Quevillon S, Joseph R, Wei CQ, Sesmilo E, Reayi A, Poondra RR, Barnes ML, Leek DM, Xu B, Lougheed C, Schapira M, Alaoui-Jamali M, Arya P. Diverse architectures on the Indoline Scaffold: the discovery of a chemical probe of focal adhesion kinase signaling networks. Bioorg Med Chem. 2008 Nov 1;16(21):9596-602.
Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008 Nov;173(5):1540-50.
Behmoaram E, Bijian K, Bismar TA, Alaoui-Jamali MA. Early stage cancer cell invasion: signaling, biomarkers and therapeutic targeting. Front Biosci. 2008 May 1;13:6314-25.
Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, Schlaepfer DD, and Alaoui-Jamali MA. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. Journal of Cell
Biology, in press.
Balys R, Alaoui-Jamali MA, Black M, and Hier M. A clinically relevant oral cancer model for serum proteomics eavesdropping on the tumor microenvironment.
Journal of Otolaryngology, in press.
Alaoui-Jamali MA, Scrivens PJ, and Loignon M. Stress-activated signal transduction pathways in DNA damage response: implications for repair, arrest, and therapeutic interventions. In "DNA Repair in Cancer
Therapy", Editors: L Panasci and MA Alaoui-Jamali, Humana Press Inc., NJ; 2004.
Alaoui-Jamali MA, Dupre I, Qiang H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resistance Updates;7(4-5):245-255, 2004.
Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol. 2005;70(4):511-9.
Mamane Y, Loignon M, Palmer J, Hernandez E, Cesaire R,
Alaoui-Jamali M, Hiscott J. Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes. J Interferon Cytokine Res. 2005;25(1):43-51.
Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude B. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J. Pharmacology Experimental Therapeutics. 2004;311(3):1163-70.
Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal
oral epithelial cells. Oncogene, 2004 Jan15;23(2):350-8.
Mathonnet G, Lachance S, Alaoui-Jamali MA, Drobetsky EA. Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutation Res. 2004 Oct 4;554(1-2):305-18.
Chow TY, Alaoui-Jamali MA, Yeh C, Yuen L, Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther. 2004 Aug;3(8):911-20.
|
